Tango Therapeutics, Inc. ((TNGX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Tango Therapeutics, Inc. is conducting a Phase 1/2 study titled ‘A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors.’ The study aims to assess the safety and effectiveness of TNG462 in treating MTAP-deleted solid tumors, a significant area of unmet medical need.
Intervention/Treatment: The study tests TNG462, a selective PRMT5 inhibitor, administered orally. It is evaluated alone and in combination with pembrolizumab, an anti-PD-1 antibody, to determine its maximum tolerated dose and recommended phase 2 dose.
Study Design: This interventional study is non-randomized with a sequential intervention model. It includes an open-label dose escalation phase followed by a dose expansion phase across five arms, focusing on treatment as the primary purpose without any masking.
Study Timeline: The study began on January 30, 2023, and is currently recruiting. The latest update was submitted on May 5, 2025, indicating ongoing progress and adjustments as necessary.
Market Implications: This study update could positively influence Tango Therapeutics’ stock performance by demonstrating progress in addressing MTAP-deleted tumors. Success in this study may enhance investor confidence and position the company favorably against competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.